{
  "abstract": "Introduction: Patients with complicated urinary tract infections (cUTIs) caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacterales (ESBL-E) not susceptible (NS) to fluoroquinolones (FQ-NS) or resistant (R) to trimethoprim-sulfamethoxazole (TMP/SMX-R) have few effective oral treatment options.\n\nMethods: Data from the Optum de-identified Electronic Health Record data set (Optum EHR) (January 2018–September 2023) were used. The primary objective was to describe cumulative incidence of treatment failure (TF) by care setting (hospital versus non-hospital) within 30 days of the initiation of the latest intravenous antibiotic treatment prescribed ± 7 days from the microbiology results (index).\n\nResults: Among 7388 eligible patients, mean (standard deviation) age was 65.6 (17.7) years, and 66.3% were female. Most patients (5211, 70.5%) had a cUTI with a complicating factor; 3415 (46.2%) were diagnosed in hospital. Among the 7902 ESBL-E isolates from eligible patients with cUTIs, Escherichia coli was the predominant pathogen (75.1%), followed by Klebsiella pneumoniae (13.4%). Overall, 6384 (81.7%) isolates were FQ-NS, 5323 (68.0%) TMP/SMX-R, and 170 (2.2%) carbapenem-NS. Kaplan-Meier estimates revealed that the cumulative incidence of TF by day 30 post-index was 27.5% among hospitalized patients and 25.2% among non-hospitalized, with variation by resistance profile, driven primarily by receipt of another antibiotic (both settings). Most patients (5013, 67.9%) were prescribed an intravenous antibiotic at index, often carbapenems (2157, 43.0%), but treatment sequences were heterogeneous. Recurrence occurred in 2116 patients (28.6%), hospitalization (among those not hospitalized at index) in 975 (24.5%), and readmission in 663 (19.4%).\n\nConclusions: These data indicate a substantial burden of cUTIs caused by ESBL-E that were FQ-NS or TMP/SMX-R, characterized by high rates of treatment failures and hospitalization for IV antibiotic treatment.\n\nSupplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s40121-026-01460-y.",
  "abstract_shown": true,
  "affiliations": [
    "University of Pittsburgh, Pittsburgh, PA USA",
    "David Geffen School of Medicine at UCLA, Los Angeles, CA USA",
    "GSK, London, UK",
    "Analysis Group Inc., Boston, MA USA",
    "Analysis Group Inc., Los Angeles, CA USA",
    "GSK, 1250 S, Collegeville Road, Collegeville, PA 19426 USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 12,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Ryan K. Shields"
    },
    {
      "affs": [
        1
      ],
      "name": "A. Lenore Ackerman"
    },
    {
      "affs": [
        2
      ],
      "name": "Myriam Drysdale"
    },
    {
      "affs": [
        3
      ],
      "name": "Rose Chang"
    },
    {
      "affs": [
        3
      ],
      "name": "Louise Yu"
    },
    {
      "affs": [
        4
      ],
      "name": "Maral DerSarkissian"
    },
    {
      "affs": [
        5
      ],
      "name": "Iain A. Gillespie"
    },
    {
      "affs": [
        3
      ],
      "name": "Megan Pinaire"
    },
    {
      "affs": [
        3
      ],
      "name": "Zhuo Chen"
    },
    {
      "affs": [
        3
      ],
      "name": "Mei Sheng Duh"
    },
    {
      "affs": [
        5
      ],
      "name": "Alanna Farrell-Foster"
    },
    {
      "affs": [
        5
      ],
      "name": "Fanny S. Mitrani-Gold"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/2wdsfmqzea50v.bib",
  "cited_by": 0,
  "doi": "10.1007/s40121-026-01460-y",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13751910/",
  "id": "2wdsfmqzea50v",
  "issns": [
    "2193-8229",
    "2193-6382"
  ],
  "landing_url": "https://doi.org/10.1007/s40121-026-01460-y",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Research"
    ],
    [
      "openalex",
      "2726|Antibiotic Resistance in Bacteria"
    ]
  ],
  "openalex": "W7221520086",
  "pdf_url": "https://link.springer.com/content/pdf/10.1007/s40121-026-01460-y.pdf",
  "pmcid": "PMC13751910",
  "pmid": "42862518",
  "published": "2026-10-12",
  "publisher": "Springer",
  "ris": "https://research.draconitic.com/paper/2wdsfmqzea50v.ris",
  "sources": [
    {
      "first_seen": "2026-11-15T12:21:24Z",
      "native_id": "PMC13751910",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s40121-026-01460-y"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2726|Antibiotic Resistance in Bacteria",
      "subfield": "infectious-disease"
    }
  ],
  "title": "Complicated Urinary Tract Infections Caused by Fluoroquinolone-Non-Susceptible/Trimethoprim-Sulfamethoxazole-Resistant Extended-Spectrum β-Lactamase-Producing Enterobacterales: Patient Characteristics, Resistance Phenotypes, Treatment Patterns, and Clinical Outcomes",
  "title_text": "Complicated Urinary Tract Infections Caused by Fluoroquinolone-Non-Susceptible/Trimethoprim-Sulfamethoxazole-Resistant Extended-Spectrum β-Lactamase-Producing Enterobacterales: Patient Characteristics, Resistance Phenotypes, Treatment Patterns, and Clinical Outcomes",
  "type": "peer-reviewed",
  "updated_at": "2026-11-15T12:21:24Z",
  "url": "https://research.draconitic.com/paper/2wdsfmqzea50v",
  "venue": "Infectious Diseases and Therapy",
  "versions": []
}